Drug intelligence / Profile preview

BN-MePPR

Development stage: Preclinical
Modality: Small Molecules
Administration: Intraperitoneal

Overview

BN-MePPR is a synthetic SN-38 derivative developed as an anticancer agent for the treatment of colorectal cancer. It is structurally related to SN-38, the active metabolite of Irinotecan, a topoisomerase I inhibitor, and has been evaluated in preclinical studies for its tumor-inhibitory efficacy and effects on gut microbiota, with antitumor activity in xenograft mouse models similar to Irinotecan[1][3]. The primary mechanism of action is presumed to be inhibition of topoisomerase I, similar to its parent compound, SN-38.

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on BN-MePPR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BN-MePPR.

Explore the full profile